Observational study finds 22% increase in Lyme disease cases in England — Evidence Review
Published by researchers at UK Health Security Agency
Researched by
— the AI search engine for science
Table of Contents
Cases of Lyme disease in England rose by 22% from 2024 to 2025, according to a new report by the UK Health Security Agency, with ongoing efforts to develop effective vaccines and treatments. Related studies consistently document rising incidence, geographic spread, and the impact of ecological and reporting factors on case detection in the UK and other countries.
- The observed year-on-year increase in laboratory-confirmed Lyme disease aligns with longer-term trends of rising incidence and expanding geographic risk documented in multiple UK-based cohort and surveillance studies 1 2 3 4 5.
- Related research highlights that reported cases may underestimate true incidence due to underdiagnosis and limitations in surveillance systems, with some studies estimating actual cases to be several times higher than laboratory confirmations 1 2.
- Socioeconomic status, rural residence, and ecological factors such as host and tick distribution all contribute to observed patterns in Lyme disease incidence, supporting the new study’s findings on the influence of environmental and behavioral factors on disease risk 2 3 4 6 8 12.
Study Overview and Key Findings
Lyme disease continues to be a growing public health concern in England, with both incidence and geographic range increasing over the last decade. The current study is timely, occurring alongside efforts by pharmaceutical companies to develop new vaccines and treatments for the disease. Importantly, the study not only provides updated incidence data but also contextualizes these trends within changing environmental factors, public awareness, and the ongoing challenges of surveillance and prevention. It further addresses the gaps in human vaccine availability and the complexity of translating veterinary advances into human health solutions.
| Property | Value |
|---|---|
| Study Year | 2025 |
| Organization | UK Health Security Agency |
| Authors | Dr Claire Gordon, Linden Hu, Julia Knight |
| Population | Individuals with Lyme disease |
| Sample Size | 1,168 laboratory-confirmed cases |
| Methods | Observational Study |
| Outcome | Incidence of Lyme disease and vaccine development |
| Results | Lyme disease cases increased by 22% from 2024 to 2025. |
Literature Review: Related Studies
To contextualize the new findings, we searched the Consensus database containing over 200 million research papers. The following search queries were used to identify relevant literature:
- Lyme disease incidence trends England
- Lyme disease epidemiology 2024 2025
- factors influencing Lyme disease prevalence
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How has Lyme disease incidence changed over time and geography? | - Incidence has risen steadily in the UK and internationally, with underdiagnosis likely leading to underestimation of true case numbers 1 2 3 4 5. - Geographic expansion is evident, with rural, higher socioeconomic status areas and southern England showing higher rates 2 4. |
| What factors drive changes in Lyme disease risk and incidence? | - Environmental variables (e.g., climate, host and predator populations, habitat changes) significantly affect tick and disease distribution 6 8 10 11 12. - Socioeconomic status, outdoor activity, and awareness also impact incidence and reporting rates 2 4 10. |
| What are the challenges in Lyme disease diagnosis, surveillance, and reporting? | - Laboratory-confirmed cases undercount true incidence, as many cases are diagnosed clinically or missed entirely 1 2 3. - Disruptions such as the COVID-19 pandemic have affected reporting accuracy and healthcare access 10. |
| What is the status and outlook for Lyme disease prevention and vaccination? | - Previous Lyme vaccines for humans were withdrawn due to low uptake and concerns over adverse effects [news article]. - New vaccines and monoclonal antibodies are in development, with trials facing statistical and practical challenges [news article, 9]. |
How has Lyme disease incidence changed over time and geography?
Multiple studies indicate that the incidence of Lyme disease in England and other temperate regions has increased over the past two decades, with both reported and estimated cases rising substantially. The new study's findings of a 22% increase in laboratory-confirmed cases from 2024 to 2025 are consistent with this broader trend, though year-to-year fluctuations are expected due to factors such as awareness, testing, and outdoor activity. Geographic analysis reveals that rural and southern areas, as well as less deprived communities, are more affected, paralleling patterns found in earlier UK and US data 1 2 3 4 5.
- The annual incidence in the UK is higher than previously believed, with estimates suggesting threefold underreporting 1.
- Hospital and laboratory data both show a steady rise, with notable increases in rural and more affluent regions 2 4.
- Increases are not unique to the UK; similar trends are observed in the US and Europe, with shifting hotspots 5 13.
- The new study’s incidence numbers fall within the expected range of recent surveillance data but likely still underestimate total cases 1 2 3.
What factors drive changes in Lyme disease risk and incidence?
Ecological and socioeconomic variables play a key role in Lyme disease risk. Changes in climate, host and predator populations, and land use influence tick abundance and infection rates, while human behavior (such as time spent outdoors) and socioeconomic status affect exposure and reporting. The new study’s emphasis on the increasing range of ticks and the effects of weather and habitat change is well-supported by related research 6 8 10 11 12.
- Environmental models have demonstrated that landscape features, host communities, and climate metrics can predict spatial and temporal patterns in tick infection rates 8 12.
- Fluctuations in predator populations (e.g., declines in foxes, increases in coyotes) can indirectly raise Lyme disease risk by altering small mammal host abundance 11 12.
- Socioeconomic status and rurality correlate with higher incidence, likely due to greater exposure to tick habitats 2 4.
- Behavioral and ecological factors together shape the observed increase in cases and geographic spread 6 8 10.
What are the challenges in Lyme disease diagnosis, surveillance, and reporting?
Surveillance systems based on laboratory-confirmed cases capture only a portion of true Lyme disease incidence. Many patients are diagnosed and treated based on clinical symptoms (notably the bullseye rash), while others may go undiagnosed or misdiagnosed. The COVID-19 pandemic further complicated data collection, as healthcare disruptions led to underreporting. These issues echo the new study’s acknowledgment that confirmed case numbers are only a partial measure of disease burden 1 2 3 10.
- Population-based cohort studies estimate total cases to be several times higher than laboratory reports suggest 1 2.
- Surveillance data are affected by changes in testing, awareness, and public health priorities 3 5 10.
- The pandemic caused sharp drops in reported cases due to reduced healthcare access and activity 10.
- Underdiagnosis is especially problematic for cases presenting without classic symptoms or in low-incidence regions 1 2 3.
What is the status and outlook for Lyme disease prevention and vaccination?
The withdrawal of the initial human Lyme vaccine and the ongoing challenges of vaccine uptake, trial design, and public trust have hampered prevention efforts. Recent advances, including mRNA and protein subunit vaccines, as well as monoclonal antibodies and tick-killing drugs, offer potential, but clinical and practical hurdles remain. The new study’s coverage of these developments aligns with the literature on the complexity of human vaccine development and the need for robust, large-scale field trials [news article, 9].
- The earlier LYMErix vaccine showed moderate efficacy but suffered from low uptake due to limited recommendations and public concerns [news article].
- New vaccine candidates are in clinical trials, but low incidence and unpredictable case rates challenge statistical validation [news article,9].
- Monoclonal antibodies and oral tick-killing drugs, some adapted from veterinary medicine, are being investigated as alternatives or adjuncts [news article].
- Public hesitancy and the relatively low—but likely underestimated—incidence in the UK may limit future vaccine adoption [news article].
Future Research Questions
Despite advances in surveillance and prevention, significant gaps remain in understanding and managing Lyme disease. Future research is needed to improve risk prediction, refine prevention strategies, and address the complex ecological and societal factors influencing incidence and reporting.
| Research Question | Relevance |
|---|---|
| How accurate are current surveillance methods for estimating true Lyme disease incidence in England? | Surveillance data likely underestimate true incidence due to clinical diagnoses without laboratory confirmation and underreporting, as highlighted by cohort studies and the new report 1 2 3. |
| What ecological and climatic factors most strongly predict Lyme disease expansion in the UK? | Understanding the influence of host, predator, and environmental changes on tick and disease distribution can guide targeted prevention and management strategies 6 8 11 12. |
| How effective and acceptable are emerging Lyme disease vaccines in human populations? | New vaccine candidates face challenges in demonstrating efficacy and gaining public trust, especially given past experiences with LYMErix and current vaccine hesitancy [news article, 9]. |
| What are the long-term outcomes and prevalence of post-treatment Lyme disease in the UK? | Persistent symptoms after antibiotic treatment are a recognized problem in the US, but less is known about their prevalence and impact in the UK context 7. |
| How do socioeconomic and behavioral factors influence Lyme disease risk and reporting in England? | Incidence is higher in rural and affluent areas, but the interplay of behavior, access to care, and awareness needs further exploration to inform equitable public health interventions 2 4 10. |